TTF

Property	Information
Drug Name	Tumor Treating Fields (TTFields)
Overview	Tumor Treating Fields (TTFields) are a groundbreaking, non-invasive cancer therapy that utilizes low-intensity, alternating electric fields to disrupt cancer cell division. Clinically approved for the treatment of newly diagnosed and recurrent glioblastoma, TTFields have demonstrated a significant extension in both progression-free and overall survival when combined with standard chemotherapy. The therapy is well-tolerated, with the most common side effect being manageable skin irritation at the application site. Ongoing studies are exploring the efficacy of TTFields in treating other aggressive tumor types.
FDA Approval	Yes
Used for	Newly diagnosed and recurrent glioblastoma; malignant pleural mesothelioma
Clinical Trial Phase	Approved; ongoing Phase III trials for other tumor types
Clinical Trial Explanation	TTFields have undergone extensive clinical evaluation, including the EF-14 Phase III trial, which demonstrated a significant survival benefit in newly diagnosed glioblastoma patients when combined with temozolomide. Ongoing Phase III trials are investigating its efficacy in other cancers such as non-small cell lung cancer, ovarian cancer, and pancreatic cancer.Property "Has clinical trial explanation" (as page type) with input value "TTFields have undergone extensive clinical evaluation, including the EF-14 Phase III trial, which demonstrated a significant survival benefit in newly diagnosed glioblastoma patients when combined with temozolomide. Ongoing Phase III trials are investigating its efficacy in other cancers such as non-small cell lung cancer, ovarian cancer, and pancreatic cancer." contains invalid characters or is incomplete and therefore can cause unexpected results during a query or annotation process.
Common Side Effects	Skin irritation at the application site, mild to moderate headache, fatigue
OS without	Not specified
OS with	Median overall survival of 20.9 months for newly diagnosed glioblastoma patients when combined with temozolomide, compared to 16.0 months with temozolomide alone
PFS without	Not specified
PFS with	Median progression-free survival of 6.7 months with TTFields plus temozolomide, versus 4.0 months with temozolomide alone
Usefulness Rating	4.5
Usefulness Explanation	TTFields offer a novel, non-invasive treatment modality that has been clinically proven to extend both progression-free and overall survival in glioblastoma patients, with minimal systemic side effects. Its integration into standard care practices provides an additional therapeutic option for patients with limited alternatives.Property "Has Usefulness Explanation" (as page type) with input value "TTFields offer a novel, non-invasive treatment modality that has been clinically proven to extend both progression-free and overall survival in glioblastoma patients, with minimal systemic side effects. Its integration into standard care practices provides an additional therapeutic option for patients with limited alternatives." contains invalid characters or is incomplete and therefore can cause unexpected results during a query or annotation process.
Toxicity Level	2
Toxicity Explanation	The primary side effect is localized skin irritation beneath the transducer arrays, which is generally manageable with topical treatments and proper skin care. Unlike traditional chemotherapies, TTFields do not cause systemic toxicities such as immunosuppression or organ dysfunction.

Notes: TTFields are delivered via a portable device (Optune) that patients can carry, allowing for continuous treatment while maintaining daily activities. Treatment adherence, defined as wearing the device for at least 18 hours per day, correlates positively with improved outcomes. Ongoing research aims to expand TTFields' application to other malignancies, including non-small cell lung cancer and pancreatic cancer.

Links: * [Novocure - Optune Device](https://www.optune.com/)

• [EF-14 Phase III Clinical Trial Results](https://pubmed.ncbi.nlm.nih.gov/26369883/)
• [FDA Approval Announcement for TTFields](https://www.fda.gov/news-events/press-announcements/fda-approves-expanded-indication-medical-device-treat-form-brain-cancer)

From Ben Williams Book: Not specified

Loading comments...